Above and Beyond Open Access

Information technology, an innovative publishing practice, and public debate synchronized in a most satisfying way over the past month.On Feb. 28, the British Medical Journal (BMJ) published an article1 entitled, "Where Is The Evidence That Animal Research Benefits Humans?" The paper purported to demonstrate that "Much animal research into potential treatments for humans is wasted because it is poorly conducted and not evaluated through systematic reviews." Unsurprisingly, the article attracted

Written byRichard Gallagher
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Information technology, an innovative publishing practice, and public debate synchronized in a most satisfying way over the past month.

On Feb. 28, the British Medical Journal (BMJ) published an article1 entitled, "Where Is The Evidence That Animal Research Benefits Humans?" The paper purported to demonstrate that "Much animal research into potential treatments for humans is wasted because it is poorly conducted and not evaluated through systematic reviews." Unsurprisingly, the article attracted much media attention, with headlines screaming, "Experiments On Animals Should End, Say Doctors" and "Animal Tests Poorly Conducted!" The findings are said to have boosted animal rights groups.

However, after a number of weeks of discussion, the question that the title asks now can be definitively answered, and the criticisms the paper raises, addressed. This has been made possible by the enlightened publishing practices of the BMJ. This journal has led the way in providing free, online access to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies